Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb
Stephen T. Joy, Matthew J. Henley, Samantha N. De Salle, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 37, pp. 15056-15062
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
J. Thomas, Mi Wang, Wei Jiang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8178-8199
Closed Access | Times Cited: 33
Effects of the Acetyltransferase p300 on Tumour Regulation from the Novel Perspective of Posttranslational Protein Modification
Qingmei Zeng, Kun Wang, Yongxiang Zhao, et al.
Biomolecules (2023) Vol. 13, Iss. 3, pp. 417-417
Open Access | Times Cited: 32
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 16
Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment
Panhong Gou, Wenchao Zhang
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116130-116130
Open Access | Times Cited: 12
KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
Kee‐Beom Kim, Ashish Kabra, Dong Wook Kim, et al.
Science Advances (2022) Vol. 8, Iss. 7
Open Access | Times Cited: 25
Dynamics and interactions of intrinsically disordered proteins
Munehito Arai, Shunji Suetaka, Koji Ooka
Current Opinion in Structural Biology (2023) Vol. 84, pp. 102734-102734
Closed Access | Times Cited: 15
High-throughput affinity measurements of direct interactions between activation domains and co-activators
Nicole DelRosso, Peter Suzuki, Daniel Griffith, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
Jie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Emerging role of MYB transcription factors in cancer drug resistance
Bernhard Biersack, Michael Höpfner
Cancer Drug Resistance (2024)
Open Access | Times Cited: 5
Transcription Factor MYB as Therapeutic Target: Current Developments
Karl‐Heinz Klempnauer
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3231-3231
Open Access | Times Cited: 4
Peptide Tethering: Pocket-Directed Fragment Screening for Peptidomimetic Inhibitor Discovery
Ashley E. Modell, Frank Marrone, Nihar R. Panigrahi, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 3, pp. 1198-1204
Open Access | Times Cited: 15
Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition
Noha A.M. Shendy, Melissa J. Bikowitz, Logan H. Sigua, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Drugging Fuzzy Complexes in Transcription
Bonnie Su, Matthew J. Henley
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 19
P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma
Cheng Cheng, Tian He, Kai Chen, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 3, pp. 100504-100504
Open Access | Times Cited: 7
Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling
Katherine Gosselé, Irene Latino, Eleen Laul, et al.
(2024)
Open Access | Times Cited: 2
Design and Biochemical Characterization of Peptidic Inhibitors of the Myb/p300 Interaction
Matthew D. Jones, Philipp Grosche, Andreas Floersheimer, et al.
Biochemistry (2023) Vol. 62, Iss. 7, pp. 1321-1329
Closed Access | Times Cited: 6
Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders
Yanhua Lei, Qing Tang, Yang Ni, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107427-107427
Closed Access | Times Cited: 2
Inhibition of CREB Binding and Function with a Dual-Targeting Ligand
Yejun Liu, Stephen T. Joy, Matthew J. Henley, et al.
Biochemistry (2023) Vol. 63, Iss. 1, pp. 1-8
Open Access | Times Cited: 5
Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy
Paloma Tejera Nevado, Tajana Tešan Tomić, Ali Atefyekta, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
A Lipopeptidomimetic of Transcriptional Activation Domains Selectively Disrupts the Coactivator Med25 Protein–Protein Interactions
Olivia N. Pattelli, Estefanía Martínez Valdivia, Matthew S. Beyersdorf, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 21
Open Access | Times Cited: 1
Rational peptide design for inhibition of the KIX–MLL interaction
Nao Sato, Shunji Suetaka, Yuuki Hayashi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Garcinolic Acid Distinguishes Between GACKIX Domains and Modulates Interaction Networks
Meghan E. Breen, Stephen T. Joy, Omari J. Baruti, et al.
ChemBioChem (2023) Vol. 24, Iss. 21
Open Access | Times Cited: 3
A Lipopeptidomimetic of Transcriptional Activation Domains Selectively Disrupts the Coactivator Med25 Protein–Protein Interactions
Olivia N. Pattelli, Estefanía Martínez Valdivia, Matthew S. Beyersdorf, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 21
Open Access
MYB as a Critical Transcription Factor and Potential Therapeutic Target in AML
Mary L. Clarke, Odd S. Gabrielsen, Jon Frampton
Advances in experimental medicine and biology (2024), pp. 341-358
Closed Access
Dysregulation of the p300/CBP histone acetyltransferases in human cancer
Longxia Xu, Hongwen Xuan, Xiaobing Shi
Epigenomics (2024) Vol. 17, Iss. 3, pp. 193-208
Closed Access
Page 1 - Next Page

Scroll to top